Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Mathew Vithayathil; Antonio D’Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Y. Wu; Celina Ang; Thomas U. Marron; Arndt Weinmann; Peter R. Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei‐Chang Lee; Yi‐Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Valentina Zanuso; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J. Pinato; Rohini Sharma

doi:10.1007/s12072-023-10491-3

Related publications

Article2023

Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomomitsu Matono, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo

Article2024

Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Sarah Cappuyns, Marta Piqué‐Gili, Roger Esteban-Fabró, Gino Philips, Ugne Balaseviciute, Roser Pinyol, Albert Gris‐Oliver, Vincent Vandecaveye, Jordi Abril‐Fornaguera, Carla Montironi, Laia Bassaganyas, Judit Peix, Marcus Zeitlhöfler, Agavni Mesropian, Júlia Huguet‐Pradell, Philipp K. Haber, Igor Figueiredo, Giorgio Ioannou, Edgar Gonzalez‐Kozlova, Antonio D’Alessio, Raphael Mohr, Tim Meyer, Anja Lachenmayer,

Article2020

Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, Ho Yeong Lim, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Yin‐Hsun Feng, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Andrew X. Zhu, Ann‐Lii Cheng

Article2025

No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study

Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Masahiro Takita, Hirokazu Chishina, M Morita, Tomoko Aoki, Tetsutaro Hamano, R. Take, Chizuko Watanabe, Kentaro Asoh, Ai Tanaka, Masatoshi Kudo

Article2022

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Y. Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara,